Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADI-PEG20 + cytarabine
- Development stage
- Discontinued
- Lead developer
- Polaris Group
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intramuscular, Subcutaneous
01
Overview
**ADI-PEG20 + cytarabine** is an investigational combination therapy consisting of pegylated arginine deiminase (ADI-PEG20) and the antimetabolite cytarabine. ADI-PEG20 is an enzyme that depletes extracellular arginine, thereby inducing selective tumor cell death in argininosuccinate synthetase–deficient (ASS-deficient) cancers (such as most acute myeloid leukemia [AML] cells). Cytarabine is a chemotherapy agent that inhibits DNA synthesis. The combination has been studied in phase I clinical trials for AML, especially in older patients or those unfit for intensive chemotherapy, seeking to improve response by targeting two complementary vulnerabilities: arginine auxotrophy and proliferative capacity of malignant cells. Polaris Pharmaceuticals developed ADI-PEG20, and the combination has been tested with low-dose cytarabine[1][2][3][4].
- Other names
- pegylated arginine deiminase + cytarabine
02
Targets
DNA polymerase family
Beyond the preview
Go deeper on ADI-PEG20 + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADI-PEG20 + cytarabine.